KR19990007777A - 면역성 및 면역자극성 올리고당 조성물 및 이를 제조하고 이용하는 방법 - Google Patents

면역성 및 면역자극성 올리고당 조성물 및 이를 제조하고 이용하는 방법

Info

Publication number
KR19990007777A
KR19990007777A KR1019970707283A KR19970707283A KR19990007777A KR 19990007777 A KR19990007777 A KR 19990007777A KR 1019970707283 A KR1019970707283 A KR 1019970707283A KR 19970707283 A KR19970707283 A KR 19970707283A KR 19990007777 A KR19990007777 A KR 19990007777A
Authority
KR
South Korea
Prior art keywords
oligosaccharide
carrier
polysaccharide
composition
conjugate
Prior art date
Application number
KR1019970707283A
Other languages
English (en)
Korean (ko)
Inventor
앤드루 제이. 말콤
Original Assignee
듀크두플레시스
알베르타리서치카운실
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/477,497 external-priority patent/US5866132A/en
Priority claimed from US08/482,626 external-priority patent/US5695768A/en
Priority claimed from CA002153733A external-priority patent/CA2153733A1/en
Priority claimed from CA002153730A external-priority patent/CA2153730A1/en
Application filed by 듀크두플레시스, 알베르타리서치카운실 filed Critical 듀크두플레시스
Publication of KR19990007777A publication Critical patent/KR19990007777A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1019970707283A 1995-06-07 1996-06-06 면역성 및 면역자극성 올리고당 조성물 및 이를 제조하고 이용하는 방법 KR19990007777A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US8/477,497 1995-06-07
US08/477,497 US5866132A (en) 1995-06-07 1995-06-07 Immunogenic oligosaccharide compositions
US08/482,626 US5695768A (en) 1995-06-07 1995-06-07 Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US8/482,626 1995-06-07
CA002153733A CA2153733A1 (en) 1995-07-12 1995-07-12 Immunogenic oligosaccharide compositions
CA2,153,730 1995-07-12
CA002153730A CA2153730A1 (en) 1995-07-12 1995-07-12 Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides
CA2,153,733 1995-07-12

Publications (1)

Publication Number Publication Date
KR19990007777A true KR19990007777A (ko) 1999-01-25

Family

ID=27427244

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970707283A KR19990007777A (ko) 1995-06-07 1996-06-06 면역성 및 면역자극성 올리고당 조성물 및 이를 제조하고 이용하는 방법

Country Status (10)

Country Link
EP (1) EP0831894A1 (ja)
JP (1) JPH11506110A (ja)
KR (1) KR19990007777A (ja)
AU (1) AU725279B2 (ja)
CZ (1) CZ327897A3 (ja)
IL (1) IL121585A0 (ja)
MX (1) MX9707944A (ja)
NO (1) NO974727L (ja)
NZ (1) NZ309713A (ja)
WO (1) WO1996040225A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE208629T1 (de) 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
PL338146A1 (en) * 1997-07-17 2000-09-25 North American Vaccine Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU760669B2 (en) 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
CA2413450C (en) * 2000-06-20 2014-02-18 Shire Biochem Inc. Streptococcus antigens
SG10201406432RA (en) * 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
KR102480429B1 (ko) * 2014-09-26 2022-12-21 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 스트렙토코커스 뉴모니에 혈청형 8에 대한 백신
EP3000820A1 (en) * 2014-09-26 2016-03-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic vaccines against Streptococcus pneumoniae serotype 8
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CN109890415B (zh) 2016-08-05 2023-04-04 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
CN109862908B (zh) 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN111050794A (zh) * 2017-09-07 2020-04-21 默沙东公司 将肺炎球菌多糖与载体蛋白缀合的配制方法
JP6950099B2 (ja) 2018-02-05 2021-10-13 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体−タンパク質複合体組成物
SG11202006387QA (en) 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3782642A4 (en) 2018-04-18 2022-04-13 SK Bioscience Co., Ltd. CAPSULE POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE AND CONJUGATES THEREOF
CA3120922A1 (en) * 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CN113607939A (zh) * 2021-08-05 2021-11-05 艾美探索者生命科学研发有限公司 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
EP0567452B1 (en) * 1990-12-18 1996-05-15 The Board Of Regents Of The University Of Washington Dialysate production system with dialysate pellets
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine

Also Published As

Publication number Publication date
NZ309713A (en) 1999-11-29
NO974727L (no) 1997-12-08
NO974727D0 (no) 1997-10-13
JPH11506110A (ja) 1999-06-02
AU725279B2 (en) 2000-10-12
MX9707944A (es) 1998-06-30
IL121585A0 (en) 1998-02-08
EP0831894A1 (en) 1998-04-01
CZ327897A3 (cs) 1998-02-18
WO1996040225A1 (en) 1996-12-19
AU5994496A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
US5866132A (en) Immunogenic oligosaccharide compositions
KR19990007777A (ko) 면역성 및 면역자극성 올리고당 조성물 및 이를 제조하고 이용하는 방법
US5695768A (en) Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
AlonsoDeVelasco et al. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines
KR102619514B1 (ko) 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
Paoletti et al. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
PL169926B1 (pl) Sposób wytwarzania kowalencyjnego koniugatu oligosacharydu z nosnikiem bialkowym PL PL PL PL PL PL PL PL
US7858101B2 (en) Modified streptococcal polysaccharides and uses thereof
Barrett Human immune responses to polysaccharide antigens: an analysis of bacterial polysaccharide vaccines in infants
Liao et al. Synthesis and immunological study of α-2, 9-oligosialic acid conjugates as anti-group C meningitis vaccines
JPH11507964A (ja) ２，５−アンヒドロ−ｄ−マンノース末端構造を持つ、抗原性グループｂ連鎖球菌▲ｉｉ▼型および▲ｉｉｉ▼型多糖断片とその複合ワクチン
Paoletti et al. Surface structures of group B Streptococcus important in human immunity
Snippe et al. Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3
Lee Bacterial capsular polysaccharides: immunogenicity and vaccines
Eby Pneumococcal conjugate vaccines
Cryz Jr et al. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines
Csordas et al. Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide
CA2153733A1 (en) Immunogenic oligosaccharide compositions
Malcolm et al. Surface layers from Bacillus alvei as a carrier for a Streptococcus pneumoniae conjugate vaccine
CA2153730A1 (en) Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides
US20110236414A1 (en) Bacterial Polysaccharide-Polypeptide Conjugate Compositions
CN101130071B (zh) 疫苗
Madoff et al. Surface structures of group B streptococci important in human immunity
CN114073761B (zh) 一种寡糖缀合物及其作为预防v型b族链球菌感染糖疫苗的应用
WESSELS et al. IMMUNITY TO GROUP B STREPTOCOCCUS

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid